Literature DB >> 14500311

Medication for sleep-wake disorders.

G Stores1.   

Abstract

Medication is indicated for only a limited number of children's sleep disorders. However, correctly chosen and supervised, pharmacological treatment may be justified and helpful. For a given sleep problem it is important to identify the underlying cause (or sleep disorder) which often calls for treatment of a non-medication type. Where medication is appropriate, cautious use and careful review of the child's physical and psychological state is essential in view of the limited information available on effectiveness and possible short and long term effects. It follows that much further research is required to establish the part medication can play in the care of children with sleep disorders, and also to define the possible effects on sleep and wakefulness of other drugs used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500311      PMCID: PMC1719336          DOI: 10.1136/adc.88.10.899

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  43 in total

1.  Developmental patterns of rhythmic suck and swallow in preterm infants.

Authors:  I H Gewolb; F L Vice; E L Schwietzer-Kenney; V L Taciak; J F Bosma
Journal:  Dev Med Child Neurol       Date:  2001-01       Impact factor: 5.449

Review 2.  REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP.

Authors:  Carlos H Schenck; Mark W Mahowald
Journal:  Sleep       Date:  2002-03-15       Impact factor: 5.849

3.  A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or new clinical entity?

Authors:  M Billiard; C Guilleminault; W C Dement
Journal:  Neurology       Date:  1975-05       Impact factor: 9.910

4.  Pro-convulsant effects of oral melatonin in neurologically disabled children.

Authors:  S H Sheldon
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

Review 5.  Toxicology of melatonin.

Authors:  B Guardiola-Lemaître
Journal:  J Biol Rhythms       Date:  1997-12       Impact factor: 3.182

6.  Contaminants in commercial preparations of melatonin.

Authors:  B L Williamson; A J Tomlinson; S Naylor; G J Gleich
Journal:  Mayo Clin Proc       Date:  1997-11       Impact factor: 7.616

7.  Clinical and polysomnographic characteristics of 34 patients with Kleine-Levin syndrome.

Authors:  N Gadoth; A Kesler; G Vainstein; R Peled; P Lavie
Journal:  J Sleep Res       Date:  2001-12       Impact factor: 3.981

8.  Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Therapy Study Group.

Authors:  A S Walters; D E Mandelbaum; D S Lewin; S Kugler; S J England; M Miller
Journal:  Pediatr Neurol       Date:  2000-03       Impact factor: 3.372

9.  Dose response to melatonin treatment for disordered sleep rhythm in a blind child.

Authors:  Anita Cavallo; William V Good; M Douglas Ris; Paul Succop
Journal:  Sleep Med       Date:  2002-03       Impact factor: 3.492

10.  Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans.

Authors:  I M McIntyre; T R Norman; G D Burrows; S M Armstrong
Journal:  Chronobiol Int       Date:  1993-06       Impact factor: 2.877

View more
  9 in total

1.  Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.

Authors:  Barry Wright; David Sims; Siobhan Smart; Ahmed Alwazeer; Ben Alderson-Day; Victoria Allgar; Clare Whitton; Heather Tomlinson; Sophie Bennett; Jenni Jardine; Nicola McCaffrey; Charlotte Leyland; Christine Jakeman; Jeremy Miles
Journal:  J Autism Dev Disord       Date:  2011-02

Review 2.  Managing attention deficit/hyperactivity disorder: unmet needs and future directions.

Authors:  C R Steer
Journal:  Arch Dis Child       Date:  2005-02       Impact factor: 3.791

Review 3.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

4.  Risk factors of sleep paralysis in a population of Polish students.

Authors:  Paulina Wróbel-Knybel; Michał Flis; Joanna Rog; Baland Jalal; Hanna Karakuła-Juchnowicz
Journal:  BMC Psychiatry       Date:  2022-06-07       Impact factor: 4.144

5.  Sleep Health Issues for Children with FASD: Clinical Considerations.

Authors:  James E Jan; Kwadwo O Asante; Julianne L Conry; Diane K Fast; Martin C O Bax; Osman S Ipsiroglu; Elizabeth Bredberg; Christine A Loock; Michael B Wasdell
Journal:  Int J Pediatr       Date:  2010-07-14

6.  Are we ignoring the problem of sleep disorder in children with intellectual disabilities?

Authors:  A M MacCrosain; M C Byrne
Journal:  Ir J Med Sci       Date:  2009-12       Impact factor: 1.568

Review 7.  Aspects of sleep disorders in children and adolescents.

Authors:  Gregory Stores
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

8.  Assessment of sleep in children with mucopolysaccharidosis type III.

Authors:  Louise Victoria Mahon; Michelle Lomax; Sheena Grant; Elaine Cross; Dougal Julian Hare; James Ed Wraith; Simon Jones; Brian Bigger; Kia Langford-Smith; Maria Canal
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

9.  Case report of adjunctive use of olanzapine with an antidepressant to treat sleep paralysis.

Authors:  Jingfeng Duan; Wanli Huang; Mincong Zhou; Xujuan Li; Wei Cai
Journal:  Shanghai Arch Psychiatry       Date:  2013-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.